Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Precise radiologic assessment of response to therapy in lymphoma patients is crucial to determine the effectiveness of treatment and subsequently forecast the relapse. This study aims to demonstrate the predictive utility of PET‐CT metabolic volumetric measures in the assessment of patients with lymphoma. A sample of 30 patients with lymphoma were selected between January 2023 to April 2024 and PET‐CT was done before therapy and post therapy and the findings were assessed. In our study, we found that the ΔSUV max of the CMR (Complete Metabolic Response) group was significantly higher than that of all other groups. The ΔSUVmax of the PMR (Partial Metabolic Response) group was significantly higher than that of the SMD (Stable Metabolic Disease) group. The ΔSUVmax of the SMD group was also significantly higher than that of the PMD (Progressive Metabolic Disease) group. Additionally, the ΔSUVmax of the PMD group was significantly lower than that of all other groups. However, the ΔSUVmax, ΔMTV and ΔTLG% from the baseline to the end of therapy could be used in prediction of patient response to treatment and determine patient prognosis. This study suggests that pre‐treatment PET/CT quantitative measures (apart from baseline SUVmax) are not conclusive in the prediction of patient response to treatment.
How to cite this article:
L. Antlin Sushma, S. Sathish Babu, B.Y. Akash Kumar and K.R. Jenish. Role of Pet CT in the Initial Assessment of Lymphoma.
DOI: https://doi.org/10.36478/10.36478/makrjms.2024.8.232.237
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2024.8.232.237